Shares of Niva Bupa Health Insurance Company Limited surged 7.52% or ₹6.11 to ₹87.40 on the NSE on May 11, among the top gainers and most active stocks on the exchange, after the standalone health insurer reported a robust 67% jump in quarterly net profit driven by strong premium growth and improved market share.
The stock hit an intraday high of ₹89.77 against a previous close of ₹81.29, and is trading comfortably above the midpoint of its 52-week range of ₹67.50 to ₹95.21. Market capitalisation stands at approximately ₹16,058 crore. The trailing P/E ratio of 470.91 reflects the high-growth, early-profitability stage of Niva Bupa’s listed journey. The stock pays no dividend currently. Average daily volume is around 8.04 lakh shares, with today’s session seeing elevated activity.
What did Niva Bupa report in Q4 FY26?
Net profit for the quarter ended March 2026 rose 67% year-on-year to ₹345 crore from ₹206 crore in Q4 FY25. Total income for the quarter grew to ₹2,078 crore from ₹1,565 crore in the year-ago period, a jump of approximately 32.8%. Total expenses for the quarter rose to ₹1,795 crore from ₹1,470 crore, reflecting the higher claims and operational costs that accompany rapid premium growth.
Gross written premium — the primary top-line metric for an insurance company — increased 38.5% year-on-year to ₹2,880 crore from ₹2,079 crore in Q4 FY25, indicating strong underlying business momentum across retail and group health insurance segments.
How did Niva Bupa’s operational metrics perform?
The company reported a claim settlement ratio of 94.4% for FY26, an improvement of 205 basis points over FY25 — a meaningful operational improvement that directly affects customer trust and retention in the health insurance segment. Retail health market share improved to 10.1% at the close of FY26, representing a 76 basis points increase over FY25, reflecting the company’s continuing gain on competitors in India’s rapidly expanding health insurance market.
However, the solvency ratio declined to 2.49 as on March 31, 2026 from 3.03 at the end of Q4 FY25. While the ratio remains above the regulatory minimum of 1.50 prescribed by IRDAI, the declining trend warrants monitoring as rapid premium growth places pressure on capital adequacy.
What else did Niva Bupa announce?
The board approved the elevation of Ankur Kharbanda — currently serving as Executive Director and Chief Business Officer — to the position of Executive Director and Deputy CEO, effective May 8, 2026, based on the recommendation of the nomination and remuneration committee. The leadership change signals continuity in the company’s senior management structure as it scales its retail health franchise.
MD and CEO Krishnan Ramachandran said market share gains and the improvement in claim settlement ratio reflect the trust customers place in the company and its continued focus on delivering superior health insurance experiences.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult a registered financial advisor before making any investment decisions. Business Upturn does not hold any position in the securities mentioned.